(1888PressRelease)
February 25, 2007 - ‘Generic Competition 2007 to 2011 - The impact of patent expiries on sales of major drugs’ published by business information supplier URCH Publishing, notes that the period 2007–11 will see the expiration of patent protection for an average of ten drugs a year in the US.
The most severely affected companies are Bristol-Myers Squibb, Takeda, AstraZeneca and Eli Lilly with greater than 40% of their revenues threatened, while Merck and Pfizer both face the serious problem of potential erosion of over 50% of their 2005 revenues.
In 2005 global sales of generic products were estimated to be $65 billion, accounting for 14% of the global healthcare market. The five year period to 2011 could see $20 billion of additional revenues generated by the generics companies, significantly enhancing their growth prospects. Sandoz
and Teva could be the beneficiaries of this growth, says the report.
The report reviews over 50 drugs due to come off patent and provides the following information for each:
The following information for each drug is provided:
- Indication
- Manufacturer
- Revenues ($m) for 2001–06 (total and US)
- % of company’s 2005 revenues
- Share of market segment
- Key competitors
- Patent Status in US, France, Germany, Italy and UK
- Patenting activity by generics companies
- Generic regulatory filing activity
- Pending litigation issues
- Share of market segment
- Impact of generic substitutes:
Directly on distributor
Indirectly on competitors
On market segment
Distributor(s)
Franchise defence strategies
The 130 page strategic report is available to buy from Piribo.com
More information about the report can be found at
http://www.piribo.com/publications/generic_drugs/generic_competition_2011.html
